JPWO2016179007A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2016179007A5 JPWO2016179007A5 JP2018508628A JP2018508628A JPWO2016179007A5 JP WO2016179007 A5 JPWO2016179007 A5 JP WO2016179007A5 JP 2018508628 A JP2018508628 A JP 2018508628A JP 2018508628 A JP2018508628 A JP 2018508628A JP WO2016179007 A5 JPWO2016179007 A5 JP WO2016179007A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dry eye
- subject
- pharmaceutically acceptable
- tear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 23
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 21
- 206010013774 Dry eye Diseases 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 13
- 108010076365 Adiponectin Proteins 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 102000011690 Adiponectin Human genes 0.000 claims description 9
- 239000000816 peptidomimetic Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010047513 Vision blurred Diseases 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 201000004356 excessive tearing Diseases 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010755 Conjunctivitis viral Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 206010067776 Ocular pemphigoid Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000028659 discharge Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 208000005494 xerophthalmia Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- -1 amino, hydroxyl Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 3
- 125000005910 alkyl carbonate group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003869 acetamides Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003858 primary carboxamides Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156127P | 2015-05-01 | 2015-05-01 | |
| US62/156,127 | 2015-05-01 | ||
| PCT/US2016/030142 WO2016179007A1 (en) | 2015-05-01 | 2016-04-29 | Adiponectin peptidomimetics for treating ocular disorders |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018514592A JP2018514592A (ja) | 2018-06-07 |
| JP2018514592A5 JP2018514592A5 (enExample) | 2019-06-13 |
| JPWO2016179007A5 true JPWO2016179007A5 (enExample) | 2022-10-27 |
| JP7245649B2 JP7245649B2 (ja) | 2023-03-24 |
Family
ID=57218292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508628A Active JP7245649B2 (ja) | 2015-05-01 | 2016-04-29 | 眼疾患を治療するためのアディポネクチンペプチド模倣薬（関連出願の相互参照） |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US10987401B2 (enExample) |
| EP (3) | EP4014985A1 (enExample) |
| JP (1) | JP7245649B2 (enExample) |
| KR (2) | KR20170141692A (enExample) |
| CN (3) | CN107530396B (enExample) |
| AU (3) | AU2016257724B2 (enExample) |
| CA (3) | CA3191203A1 (enExample) |
| DK (1) | DK3288577T3 (enExample) |
| ES (1) | ES2903448T3 (enExample) |
| IL (1) | IL272449A (enExample) |
| SG (1) | SG11202001140UA (enExample) |
| WO (2) | WO2016179007A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3191203A1 (en) * | 2015-05-01 | 2016-11-10 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
| KR20200004789A (ko) * | 2017-03-09 | 2020-01-14 | 알리스타 파마슈티컬즈, 인크. | 안구 건조증 질환을 위한 펩티드 |
| CN107149676A (zh) * | 2017-05-05 | 2017-09-12 | 杨硕 | 脂联素和脂联素/胰岛素混合液在改善及治疗眼表角膜上皮及神经损伤中的应用 |
| WO2019061491A1 (en) * | 2017-09-30 | 2019-04-04 | Pro Sunfun Biotech Research And Development Co., Ltd. | PEPTIDE FOR OCULAR CARE, COMPOSITION AND METHOD OF USE THEREOF |
| CN109912685B (zh) * | 2017-12-13 | 2022-05-06 | 三凡生技研发股份有限公司 | 眼睛保护胜肽及其组合物及使用该胜肽的用途 |
| WO2019182905A1 (en) * | 2018-03-23 | 2019-09-26 | Arch Biosurgery, Inc. | Sap and peptidomimetics for treatment of eye disease |
| US12201668B2 (en) * | 2018-10-24 | 2025-01-21 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics formulations |
| JP7699426B2 (ja) * | 2018-11-30 | 2025-06-27 | ロート製薬株式会社 | 光線による障害からの細胞保護用眼科組成物 |
| MX2022003324A (es) | 2019-09-18 | 2022-04-18 | Alcon Inc | Insertos oculares de hidrogel blando envasados en humedo. |
| US11229549B2 (en) * | 2019-09-18 | 2022-01-25 | Vance M. Thompson | Tear transplantation and multi-part contact lens with absorbent portion |
| US11213551B1 (en) | 2021-04-05 | 2022-01-04 | Korb Research, Llc. | Ocular treatment compositions and methods of use thereof |
| WO2023069255A1 (en) * | 2021-10-20 | 2023-04-27 | Stealth Biotherapeutics Inc. | Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions |
| KR20240108412A (ko) * | 2021-10-20 | 2024-07-09 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물 |
| WO2023107796A1 (en) * | 2021-12-11 | 2023-06-15 | The Regents Of The University Of California | Ophthalmic formulations for macular degeneration |
| WO2024180472A1 (en) | 2023-02-28 | 2024-09-06 | Alcon Inc. | Ocular inserts |
| KR102609115B1 (ko) * | 2023-06-08 | 2023-12-05 | 주식회사 엔큐라젠 | 펩타이드를 포함하는 안구 질환의 치료용 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| CN100335503C (zh) | 1998-04-28 | 2007-09-05 | 应用研究系统Ars股份公司 | 多元醇干扰素β偶联物 |
| GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| CA2473781A1 (en) | 2002-01-18 | 2003-07-31 | Protemix Corporation Limited | Glycoisoforms of adiponectin and uses thereof |
| NZ563187A (en) * | 2005-04-29 | 2010-05-28 | Univ California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| WO2012142142A2 (en) | 2011-04-12 | 2012-10-18 | Temple University - Of The Commonwealth System Higher Education | Adiponectin receptor agonists and methods of use |
| KR101438744B1 (ko) * | 2012-08-02 | 2014-09-15 | 전남대학교산학협력단 | 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물 |
| WO2014066775A1 (en) * | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
| CA3191203A1 (en) | 2015-05-01 | 2016-11-10 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
-
2016
- 2016-04-29 CA CA3191203A patent/CA3191203A1/en active Pending
- 2016-04-29 JP JP2018508628A patent/JP7245649B2/ja active Active
- 2016-04-29 EP EP21204663.5A patent/EP4014985A1/en not_active Withdrawn
- 2016-04-29 CN CN201680023972.XA patent/CN107530396B/zh active Active
- 2016-04-29 AU AU2016257724A patent/AU2016257724B2/en active Active
- 2016-04-29 EP EP16789840.2A patent/EP3288577B1/en active Active
- 2016-04-29 ES ES16789840T patent/ES2903448T3/es active Active
- 2016-04-29 CN CN202210970186.8A patent/CN115919996A/zh active Pending
- 2016-04-29 WO PCT/US2016/030142 patent/WO2016179007A1/en not_active Ceased
- 2016-04-29 DK DK16789840.2T patent/DK3288577T3/da active
- 2016-04-29 US US15/571,039 patent/US10987401B2/en active Active
- 2016-04-29 CA CA2981822A patent/CA2981822C/en active Active
- 2016-04-29 KR KR1020177031104A patent/KR20170141692A/ko not_active Ceased
-
2017
- 2017-08-14 US US15/676,968 patent/US10537608B2/en active Active
-
2018
- 2018-08-07 SG SG11202001140UA patent/SG11202001140UA/en unknown
- 2018-08-07 AU AU2018318008A patent/AU2018318008A1/en not_active Abandoned
- 2018-08-07 CA CA3071670A patent/CA3071670A1/en active Pending
- 2018-08-07 KR KR1020207007015A patent/KR20200039749A/ko not_active Ceased
- 2018-08-07 CN CN201880052451.6A patent/CN111032070A/zh active Pending
- 2018-08-07 EP EP18845611.5A patent/EP3668530A4/en not_active Withdrawn
- 2018-08-07 WO PCT/US2018/045527 patent/WO2019036223A1/en not_active Ceased
-
2019
- 2019-11-24 US US16/693,355 patent/US11273197B2/en active Active
-
2020
- 2020-02-04 IL IL272449A patent/IL272449A/en unknown
-
2021
- 2021-01-11 US US17/146,397 patent/US11464825B2/en active Active
- 2021-05-20 AU AU2021203254A patent/AU2021203254A1/en not_active Abandoned
-
2022
- 2022-02-24 US US17/680,181 patent/US20220331393A1/en not_active Abandoned
- 2022-10-04 US US17/937,849 patent/US20230074446A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2016179007A5 (enExample) | ||
| Greaves et al. | Treatment of diseases of the eye with mucoadhesive delivery systems | |
| JP5583310B2 (ja) | 眼球の症状の予防及び治療のための眼科用製剤 | |
| CA2806942C (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| US20070265353A1 (en) | Eye Drops for the Treatment of Dry Eye | |
| US20060172972A1 (en) | Formulation and method for administration of ophthalmologically active agents | |
| KR20120104980A (ko) | 각막 및 결막의 병변을 치료하기 위한 프로스타글란딘 ｆ2알파 및 유사체의 용도 | |
| JP2008520671A (ja) | 眼科用組成物および眼の治療方法 | |
| RU2632107C2 (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| Li et al. | Glaucoma and ocular surface disease: more than meets the eye | |
| CA3095073A1 (en) | Sap and peptidomimetics for treatment of eye disease | |
| Scelfo et al. | Ocular surface disease in glaucoma patients | |
| JP2024079810A (ja) | キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤 | |
| JP6480640B2 (ja) | イマチニブを有効成分として含む眼球乾燥疾患予防及び治療用薬学組成物 | |
| CA3168849A1 (en) | Mucoadhesive solid or semisolid ocular delivery systems based on preactivated thiomers | |
| US20210060125A1 (en) | METHOD AND USE OF PnPP-19 FOR PREVENTING AND TREATING EYE DISEASES | |
| JP2007537282A (ja) | ドライアイ障害およびブドウ膜炎を処置するための方法 | |
| JP4249185B2 (ja) | 涙液異常の治療のための眼科用組成物 | |
| RU2847424C1 (ru) | Контактная линза для доставки лекарственного средства | |
| US20250161403A1 (en) | Peptides and methods of use thereof in treating ocular disorders | |
| Irfan | Original research The Efficacy & Safety of 0. 3% Acetylcysteine eyedrops in Filamentary keratitis | |
| US20210052582A1 (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
| Duan | A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications | |
| Ermiş | Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma | |
| CN112915090A (zh) | 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法 |